Meeting
2013 ASCO Annual Meeting
Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer.
Authors
Jason R. Brown
Yale School of Medicine, New Haven, CT
Jason R. Brown , Donald R. Lannin , Brigid K. Killelea , Michael DiGiovanna , David Rimm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1085)
DOI
10.1200/jco.2013.31.15_suppl.1085
Abstract #
1085
Poster Bd #
24D
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER+) breast cancer.
First Author: Steven Allen Buechler
Poster
2017 ASCO Annual Meeting
Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.
First Author: Oleg Gluz
Poster
2013 ASCO Annual Meeting
Predictive factors for pathologic complete response (pCR) to trastuzumab(T)-based neoadjuvant chemotherapy in HER2+ breast cancer (BC) women treated in the National Cancer Institute (NCI) of Mexico.
First Author: Erika Sifuentes
Poster
2013 ASCO Annual Meeting
Prognostic significance of reduction rate of Ki-67 after neoadjuvant chemotherapy in breast cancer patients with non-pCR.
First Author: Nobuaki Matsubara